GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (CHIX:XVIVOs) » Definitions » Gross Profit

Xvivo Perfusion AB (CHIX:XVIVOS) Gross Profit : kr558.5 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Xvivo Perfusion AB Gross Profit?

Xvivo Perfusion AB's gross profit for the three months ended in Sep. 2024 was kr147.9 Mil. Xvivo Perfusion AB's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was kr558.5 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Xvivo Perfusion AB's gross profit for the three months ended in Sep. 2024 was kr147.9 Mil. Xvivo Perfusion AB's Revenue for the three months ended in Sep. 2024 was kr198.5 Mil. Therefore, Xvivo Perfusion AB's Gross Margin % for the quarter that ended in Sep. 2024 was 74.53%.

Xvivo Perfusion AB had a gross margin of 74.53% for the quarter that ended in Sep. 2024 => Durable competitive advantage

During the past 12 years, the highest Gross Margin % of Xvivo Perfusion AB was 76.44%. The lowest was 70.66%. And the median was 73.30%.


Xvivo Perfusion AB Gross Profit Historical Data

The historical data trend for Xvivo Perfusion AB's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Gross Profit Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 162.81 129.73 188.28 296.96 445.11

Xvivo Perfusion AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 107.60 117.23 135.11 158.24 147.93

Competitive Comparison of Xvivo Perfusion AB's Gross Profit

For the Medical Devices subindustry, Xvivo Perfusion AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Gross Profit distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Gross Profit falls into.



Xvivo Perfusion AB Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Xvivo Perfusion AB's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=597.542 - 152.431
=445.1

Xvivo Perfusion AB's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=198.48 - 50.549
=147.9

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr558.5 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Xvivo Perfusion AB's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=147.9 / 198.48
=74.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Xvivo Perfusion AB  (CHIX:XVIVOs) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Xvivo Perfusion AB had a gross margin of 74.53% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Xvivo Perfusion AB Gross Profit Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB Business Description

Traded in Other Exchanges
Address
Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB Headlines

No Headlines